INGEVITY CORP. DL-,01

Evotherm P35 from Ingevity has received approval from the Federal Highway Research Institute (BASt) for use in warm-mix asphalt applications in Germany. The approval followed a multi-year technical evaluation with performance tests under real traffic and environmental conditions; the product met the criteria for durability and long-term performance. Investors reacted positively: the stock traded near its 52-week high and has gained 64% over the past year. » Mere på de.investing.com

Ingevity reports Q1 2026 adjusted EPS of $1.15 (expectation $0.83) on revenue of $258 million versus projected $279 million; the stock then fell about 4.9%. Adjusted EBITDA remained nearly steady at $91.5 million, while free cash flow was negative $12 million. The company spent $52 million on share buybacks, completed portfolio divestitures and slightly lowered its full-year outlook (adjusted EPS $4.70–5.20; revenue $1.05–1.15 billion; adjusted EBITDA $370–395 million). Management emphasizes strategic realignment and balance-sheet discipline, but investors remain cautious due to the revenue miss and negative cash flow. » Mere på de.investing.com

Shares of Ingevity rose to a new 52-week high of $77.61 and are currently trading just below that at around $77.36. Over the past year the stock gained about 130% and is up 27% year-to-date; market capitalization is roughly $2.69 billion. Fourth-quarter 2025 revenue was $278 million (above expectations) with EPS of $0.64 (below expectations). Ingevity sold its road-marking business Ozark Materials to PPG for about $65 million, and analysts raised price targets (BMO $83, Jefferies $82). » Mere på de.investing.com